Astria Therapeutics (NASDAQ:ATXS) Upgraded by Cantor Fitzgerald to “Strong-Buy” Rating

Cantor Fitzgerald upgraded shares of Astria Therapeutics (NASDAQ:ATXS) to a strong-buy rating in a report released on Tuesday,Zacks.com reports.

A number of other brokerages also recently issued reports on ATXS. JMP Securities began coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $30.00.

Astria Therapeutics Stock Up 3.2 %

ATXS stock opened at $5.12 on Tuesday. The business has a fifty day moving average of $5.48 and a two-hundred day moving average of $8.01. Astria Therapeutics has a 52-week low of $3.56 and a 52-week high of $12.92. The stock has a market cap of $288.94 million, a price-to-earnings ratio of -2.45 and a beta of 0.68.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.01. As a group, sell-side analysts anticipate that Astria Therapeutics will post -1.65 EPS for the current year.

Institutional Trading of Astria Therapeutics

Several large investors have recently added to or reduced their stakes in ATXS. GAMMA Investing LLC boosted its stake in Astria Therapeutics by 1,127.4% during the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 7,971 shares during the period. California State Teachers Retirement System grew its holdings in Astria Therapeutics by 9.9% during the 4th quarter. California State Teachers Retirement System now owns 32,561 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 2,935 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Astria Therapeutics by 13.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,452 shares of the biotechnology company’s stock worth $567,000 after purchasing an additional 7,756 shares during the last quarter. Vestal Point Capital LP lifted its holdings in Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after buying an additional 180,000 shares during the period. Finally, Sphera Funds Management LTD. grew its stake in shares of Astria Therapeutics by 2.4% during the fourth quarter. Sphera Funds Management LTD. now owns 139,800 shares of the biotechnology company’s stock worth $1,250,000 after purchasing an additional 3,218 shares during the period. 98.98% of the stock is owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.